TIBER CREEK GROUP for PHRMA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Changes to the 340b program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
Health Issues HCR
Medicaid Drug Rebates. Reforms to Medicare Part D. S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. S.27, Preserve Access to Affordable Generics Act. Implementation of Comparative Effectiveness Research. Reauthroization of the Prescription Drug User Fee Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| ANDREW MCKECHNIE New | Health Policy Advisor, Sen. Finance Committee |
| SHEILA MURPHY | — |
Medicare/Medicaid MMM
Medicaid Drug Rebates. Reforms to Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| ANDREW MCKECHNIE New | Health Policy Advisor, Sen. Finance Committee |
| SHEILA MURPHY | — |
Copyright/Patent/Trademark CPT
S.27, Preserve Access to Affordable Generics Act; 340b provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| JUSTIN MCCARTHY | — |
| ANDREW MCKECHNIE New | Health Policy Advisor, Sen. Finance Committee |
Pharmacy PHA
S.319, Pharmaceutical Market Access and Drug Safety Act of 2011. Changes to the 340b program. S.27, Preserve Access to Affordable Generics Act. Reauthroization of the Prescription Drug User Fee Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.